Todos os estudos
RecrutamentoFASE2INTERVENCIONISTA

A Study of TYRA-300 in Children With Achondroplasia: BEACH301

The BEACH301 study is exploring a new medication called TYRA-300 for children aged 3 to 10 who have achondroplasia. Achondroplasia is a condition that affects how bones grow, leading to shorter limbs. This study aims to understand if TYRA-300 is safe for children, how well their bodies handle it, and to identify the most effective dose. The children taking part still have 'open growth plates', which are areas in their bones where growth happens. This is a Phase 2 study, meaning it's an early step to gather more information after initial safety tests. The goal is to see if this medicine could help children with achondroplasia grow more effectively.

Em resumo

Status
Recrutamento
Fase
FASE2
Patrocinador
Tyra Biosciences, Inc
Meta de inscrição
92
Iniciar
04 Mar 2025
Conclusão estimada
01 Jun 2030

Sobre o que é este estudo?

This study, known as BEACH301, is testing a new medicine called TYRA-300 for children who have a condition called achondroplasia. Achondroplasia is a genetic condition that affects how bones grow, particularly in the arms and legs, leading to shorter limbs. The study includes children aged 3 to 10 years old who still have 'open growth plates' – these are parts of their bones that are still growing.

The main goals of this study are to see if TYRA-300 is safe for children to take, how well their bodies tolerate it (meaning if they have uncomfortable side effects), and to figure out the right amount of medicine (the dose) that might be helpful. This is a 'Phase 2' study, which means it’s an important step in researching new medicines. It helps us learn more about the medicine's effects in people after initial safety checks.

Researchers are looking at different doses of TYRA-300 in this study. They hope to find a dose that could potentially help children with achondroplasia grow. The study is designed to carefully observe how children respond to the medicine and to gather crucial information for its future development.

Pontos principais

  • This study is for children aged 3-10 with achondroplasia.
  • It tests a new medicine, TYRA-300, taken by mouth.
  • The main goals are to check safety, tolerability, and find the right dose.
  • Children must have 'open growth plates' to join.
  • Parents and children must agree to participate.
  • Participation involves regular clinic visits and monitoring.

Quem pode ser elegível?

To join this study, children need to be between 3 and 10 years old. They must have a confirmed diagnosis of achondroplasia and still have 'open growth plates,' which are the areas in their bones that allow them to grow. It's also important that they can stand and walk by themselves and can take medicine by mouth.

There are a few specific groups within the study. Some children (aged 5-10) will be in a 'safety group' first. Others (aged 3-10) will either not have had any previous growth-boosting treatments, or they will have had such treatments in the past. Parents or legal guardians must give their permission for their child to take part, and if old enough, the child will also be asked if they want to participate.

Children cannot join the study if they have other serious health conditions that might interfere with the study or their growth, or if they have certain eye problems. Those who have had or plan to have limb-lengthening surgery, or who are taking certain other medications, also won't be able to participate.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Is your child between 3 and 10 years old?
  2. Does your child have a confirmed diagnosis of achondroplasia?
  3. Does your child's doctor confirm they have 'open growth plates'?
  4. Can your child stand and walk on their own?
  5. Can your child take medicine by mouth?
  6. Has your child not had limb-lengthening surgery or planned for one soon?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If your child takes part in this study, they will receive the study medicine, TYRA-300, which is taken by mouth. The study involves several visits to a clinic where doctors and nurses will check your child's health, measure their growth, and take blood samples to see how the medicine is working and to monitor for any side effects. These visits will help the researchers understand how safe the medicine is and what dose might be most effective.

Your child will be carefully monitored throughout the study. The study duration is not specified in detail, but it will involve regular check-ups and follow-up appointments. The medical team will explain the full schedule of visits and assessments before you decide to participate.

Riscos e benefícios potenciais

Taking part in any study has potential benefits and risks. A potential benefit of joining this study could be that your child receives a new medicine that might help with their growth due to achondroplasia. However, there's no guarantee the medicine will work for every child, and it might not work at all. Potential risks include experiencing side effects from the medicine, which could be mild or more serious, though the study aims to find a safe dose. There are also risks associated with clinic visits and procedures like blood tests. You and your child have the right to withdraw from the study at any time, for any reason, without it affecting your child's future medical care.

Locations (25)

  • Lundquist Institute for Biomedical Innovation
    Código postal verificado
    Torrance, Estados Unidos· Recrutamento
  • Children's Hospital Colorado
    Código postal verificado
    Aurora, Estados Unidos· Recrutamento
  • Nemours Alfred I duPont Hospital for Children
    Código postal verificado
    Wilmington, Estados Unidos· Recrutamento
  • Faculdade de Medicina da Universidade Johns Hopkins
    Código postal verificado
    Baltimore, Estados Unidos· Recrutamento
  • Uncommon Cures
    Código postal verificado
    Chevy Chase, United States· Recrutamento
  • University of Missouri
    Código postal verificado
    Columbia, Estados Unidos· Recrutamento
  • Washington University
    Código postal verificado
    St Louis, Estados Unidos· Recrutamento
  • Duke University Hospital
    Código postal verificado
    Durham, Estados Unidos· Recrutamento
  • Vanderbilt University Medical Center
    Código postal verificado
    Nashville, Estados Unidos· Recrutamento
  • Children's Medical Center, Dallas
    Código postal verificado
    Dallas, Estados Unidos· Recrutamento
  • University of Texas Health Science Center Medical School at Houston
    Código postal verificado
    Houston, Estados Unidos· Recrutamento
  • University of Wisconsin-Madison
    Código postal verificado
    Madison, Estados Unidos· Recrutamento

Perguntas frequentes

What is achondroplasia?

Achondroplasia is a genetic condition that affects bone growth, leading to shorter arms and legs.

What does 'open growth plates' mean?

It means the areas in your child's bones where growth normally happens are still active and open.

Is TYRA-300 a pill?

Yes, TYRA-300 is a medicine that children will take by mouth.

What is a 'Phase 2' study?

It's an early stage of testing a new medicine in people to see if it's safe and if it works.

Will my child definitely grow taller in this study?

There's no guarantee the medicine will work for every child, as this study is still trying to find out if it is effective.

Como saber mais

Lara Balick

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "A Study of TYRA-300 in Children With Achondroplasia: BEACH30…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.